Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
LetterLetters

The term cognition-enhancing medications is misleading

Joel R. Lexchin
Canadian Family Physician November 2018, 64 (11) 792;
Joel R. Lexchin
Toronto, Ont
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

The subheading “Cognition-enhancing medications” in the article by Lee and colleagues is misleading.1 Drugs for treating dementia do not enhance cognition; at best, they have minimal effects on cognition or marginally slow the decline in cognitive function.

A Cochrane review of memantine looked at the evidence in 3 different groups of patients with dementia. In those with moderate to severe Alzheimer disease there was a small beneficial effect on cognition at 6 months (2.97 points on the 100-point Severe Impairment Battery). In mild to moderate Alzheimer disease, the effect on cognition was barely clinically detectable, and for mild to moderate vascular dementia the effect on cognition was not supported by clinical global measures.2 After 26 weeks of treatment, rivastigmine only slowed the rate of cognitive decline; it did not enhance cognition.3 Donepezil versus placebo led to a 2- to 3-point mean difference in score on the Alzheimer’s Disease Assessment Scale 70-point cognitive subscale. Galantamine at a dose of 16 to 24 mg/d improved the score by about 3.4 points but led to more withdrawals due to adverse effects and caused cholinergic adverse effects in up to 20% of patients.4

The independent French drug bulletin Prescrire International concluded that, “at best, drugs for Alzheimer’s disease can only stabilize or slightly improve cognitive function, in only a minority of patients,”5 reflecting the change in rating of medical benefit for these drugs by the French Pharmacoeconomic Committee from “major” to “low.”6

In support of their recommendations for the use of “cognition-enhancing medications” the authors cite an article in the Canadian Geriatrics Society Journal of CME.7 The lead author of that paper was Dr Lee, who was also the lead author of the paper in Canadian Family Physician.1 In her earlier article, Dr Lee acknowledged receiving educational grants or honoraria from Pfizer, Janssen-Ortho, Novartis, AstraZeneca, and Solvay. The other 3 authors of that article also listed conflicts with various companies that make drugs to treat dementia.7 In the recent article, Dr Lee did not list any conflicts of interest.1

Ahn et al looked at the association between the presence of individual principal investigators’ financial ties to the manufacturer of the study drug in randomized controlled trials and the trial’s outcomes after accounting for the source of research funding.8 They concluded that the financial ties of principal investigators were independently associated with positive clinical trial results. Whether the same conclusion applies to authors of narrative review articles was not investigated.

Misleading titles and subheadings might influence the way readers interpret the material that follows and should be avoided.

Footnotes

  • Competing interests

    In 2015 to 2018, Dr Lexchin was a paid consultant on 3 projects: the first looking at indication-based prescribing (United States Agency for Healthcare Research and Quality), a second developing principles for conservative diagnosis (Gordon and Betty Moore Foundation), and a third deciding what drugs should be provided free of charge by general practitioners (Government of Canada, Ontario Strategy for Patient-Oriented Research Support Unit, and the St Michael’s Hospital Foundation). He also received payment for being on a panel that discussed a pharmacare plan for Canada (The Canadian Institute, a for-profit organization), for being on a panel at the American Diabetes Association, for a talk at the Toronto Reference Library, and for writing a brief for a law firm. He is currently a member of research groups that are receiving money from the Canadian Institutes of Health Research and the Australian National Health and Medical Research Council. He is member of the Foundation Board of Health Action International and a board member of Canadian Doctors for Medicare.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Lee L,
    2. Patel T,
    3. Molnar F,
    4. Seitz D
    . Optimizing medications in older adults with cognitive impairment. Considerations for primary care clinicians. Can Fam Physician 2018;64:646-52. (Eng), e366–72 (Fr).
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. McShane R,
    2. Areosa Sastre A,
    3. Minakaran N
    . Memantine for dementia. Cochrane Database Syst Rev 2006;(2):CD003154.
  3. 3.↵
    1. Birks JS,
    2. Chong LY,
    3. Grimley Evans J
    . Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2015;(9):CD001191.
  4. 4.↵
    1. Therapeutics Initiative.
    Drugs for Alzheimer’s disease. Ther Lett. Vol. 56. 2005. p. 1-2. Available from: https://www.ti.ubc.ca/wordpress/wp-content/uploads/2010/08/56.pdf. Accessed 2018 Oct 9.
    OpenUrl
  5. 5.↵
    Drugs for Alzheimer’s disease: best avoided. No therapeutic advantage. Prescrire Int 2012;21(128):150.
    OpenUrlPubMed
  6. 6.↵
    1. Commission de la transparence, Haute autorité de santé.
    Réévaluation des médicaments indiqués dans le traitement symptomatique de la maladie d’Alzheimer. Rapport d’évaluation. Saint-Denis La Plaine, Fr: Haute autorité de santé; 2011.
  7. 7.↵
    1. Lee L,
    2. Rojas-Fernandez C,
    3. Heckman G,
    4. Gagnon M
    . Cognition-enhancing drugs in dementia: tips for the primary care physician. Can Geriatr Soc J CME. Vol. 1.(1) 2011. p. 5-9. Available from: http://canadiangeriatrics.ca/2011/12/volume-1-issue-1-cognition-enhancing-drugs-in-dementia/. Accessed 2018 Oct 9.
    OpenUrl
  8. 8.↵
    1. Ahn R,
    2. Woodbridge A,
    3. Abraham A,
    4. Saba S,
    5. Korenstein D,
    6. Madden E,
    7. et al
    . Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. BMJ 2017;356:i6770.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Family Physician: 64 (11)
Canadian Family Physician
Vol. 64, Issue 11
1 Nov 2018
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The term cognition-enhancing medications is misleading
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The term cognition-enhancing medications is misleading
Joel R. Lexchin
Canadian Family Physician Nov 2018, 64 (11) 792;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
The term cognition-enhancing medications is misleading
Joel R. Lexchin
Canadian Family Physician Nov 2018, 64 (11) 792;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Excellent chronic pain guideline
  • Treating the vaccine hesitant
  • Francophone participation at Family Medicine Forum
Show more Letters

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2022 by The College of Family Physicians of Canada

Powered by HighWire